(Q36478226)

14 August 2017

Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

3

Meir J Stampfer

1 reference

14 August 2017

4

Edward L Giovannucci

1 reference

14 August 2017

Preet K Dhillon

1

1 reference

14 August 2017

Stacey A Kenfield

series ordinal

2

1 reference

14 August 2017

June M Chan

series ordinal

5

1 reference

14 August 2017

7 September 2012

1 reference

Cancer Prevention Research

14 August 2017

1 reference

14 August 2017

5

1 reference

14 August 2017

10

1 reference

14 August 2017

1223-1228

1 reference

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Risk factors for prostate cancer incidence and progression in the health professionals follow-up study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Reproducibility and Validity of an Expanded Self-Administered Semiquantitative Food Frequency Questionnaire among Male Health Professionals

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

The TNM classification of prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Aspirin and hormone therapy for prostate cancer

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3526345

Test of the National Death Index

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22961777

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identification of bone marrow micrometastases in patients with prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22961777

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22961777

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1940-6207.CAPR-12-0171

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

22961777

1 reference